Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 55,936 shares at $124.78 ($6.9M) on 2016-02-23, disclosed to the SEC on 2016-02-24.
Open-market sale of $6.9M JAZZ by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $120.68 | 2,716 | $328K | 4.8% |
| 2 | $120.68 | 2,716 | $328K | 4.8% |
| 3 | $122.03 | 4,779 | $583K | 8.5% |
| 4 | $122.03 | 4,779 | $583K | 8.5% |
| 5 | $122.83 | 15,824 | $1.9M | 28.3% |
| 6 | $122.83 | 15,824 |
| $1.9M |
| 28.3% |
| 7 | $123.81 | 2,927 | $362K | 5.3% |
| 8 | $123.81 | 2,927 | $362K | 5.3% |
| 9 | $124.78 | 1,722 | $215K | 3.1% |
| 10 | $124.78 | 1,722 | $215K | 3.1% |
| Total | $122.71 avg | 55,936 | $6.9M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |